A peptoid-based inhibitor of protein arginine methyltransferase 1 (PRMT1) induces apoptosis and autophagy in cancer cells

DuBose, Mollie B; Sartawi, Tala; Sawatzky, Tina M; Causey, Corey P.; Rehman, Fatima; Knuckley, Bryan

doi:10.1016/j.jbc.2022.102205

Search citation statements

Order By: Relevance

Paper Sections

Select...

Cyclic Peptoids As Ptc In Asymmetric Catalysis1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2025

Publication Types

Select...

Article6

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 11 publications

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since 2007, when Kirshenbaum and co-workers reported the first cyclopeptoid hetero oligomers [55], a great deal of research interest has been devoted to the synthesis of novel cyclopeptoids. Macrocyclic peptoids have shown remarkable biological properties [56] such as antitumor [57][58][59], antimicrobial [60][61][62][63][64], glycosidase inhibition [65][66][67] and ionophoric activities [68][69][70]. Some of these features are a direct consequence of the cation-binding ability of the macrocyclic scaffold [71][72][73][74][75][76].…”

Section: Cyclic Peptoids As Ptc In Asymmetric Catalysismentioning

confidence: 99%

Peptidomimetic-Based Asymmetric Catalysts

2023

View full text Add to dashboard Cite

Despite the great advantages of peptidomimetic scaffolds, there are only a few examples of their application in the field of asymmetric catalysis. Peptidomimetic scaffolds offer numerous advantages related to their easy preparation, modular and tunable structures, and biomimetic features, which make them well suited as chiral catalysts. This review underlines the structure–function relationship for catalytic properties towards efficient enantioselective catalysis.

show abstract